Navigation Links
Institute for Aging Research study finds delirium presentation predicts mortality
Date:7/6/2009

(Boston, Mass)The way certain patients present in the post-acute hospital setting with delirium, a common, preventable but life-threatening acute confusional state, predicts mortality, according to a study conducted by the Institute for Aging Research of Hebrew SeniorLife.

Patients with severe, hypoactive delirium, characterized by slowing or lack of movement and unresponsiveness, have the worst six-month survival rate of any class of the disease. Those with mild, hypoactive delirium have a significantly higher likelihood of dying than patients with other, milder symptoms.

"The association of the delirium classes on mortality depends on the presence or absence of dementia," says lead author Frances Yang, Ph.D., an assistant scientist at the Institute for Aging Research and an instructor in psychiatry at Brigham and Women's Hospital and Harvard Medical School. "Among patients who did not have dementia, it was delirium severity rather than motoric subtype that was associated with higher risk of mortality at six months."

The study, published in the May/June issue of the journal Psychosomatics, is the first to link characteristics of delirium, called subtypes, with disease severity. The four subtypes of delirium are normal, hypoactive, hyperactive (symptoms range from mild restlessness to constant movement and agitation) and mixed, which combines both hypo- and hyperactive elements.

Using two standard assessment tools, researchers at the Institute's Aging Brain Center examined whether the classic psychomotor subtypes of delirium are reflected by delirium severity. In addition, they sought to determine if the subtypes were able to predict mortality.

Dr. Yang's co-author, Edward Marcantonio, M.D., an associate professor of medicine at Beth Israel Deaconess Medical Center and Harvard Medical School, and colleagues screened more than 4,000 patients at eight Boston-area skilled nursing facilities using the Confusion Assessment Method and the Memorial Delirium Assessment Scale, two standard tools to detect delirium. More than 400 of these patients were found to have delirium and were followed over six months.

Delirium is an acute and relatively suddenover hours or daysdecline in attention, perception and cognition. It is generally caused by severe physical illness, often in the elderly, or any process that interferes with the normal metabolism and function of the brain. An estimated 14 percent to 24 percent of patients admitted to the hospital suffer from episodes of delirium. A recent study by Aging Brain Center investigators found that delirium rapidly accelerates memory decline in Alzheimer's disease patients.

"Our data reinforce the need to systematically assess patients for delirium at post-acute care admission, while considering dementia status," says Dr. Yang. "The findings demonstrate the importance of examining psychomotor subtype and the severity of delirium in predicting mortality."


'/>"/>

Contact: Scott Edwards
Edwards@hrca.harvard.edu
781-247-8172
Hebrew SeniorLife Institute for Aging Research
Source:Eurekalert

Related medicine news :

1. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
2. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
3. LifeNet Health Establishes The Skin & Wound Allograft Institute
4. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
5. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
6. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
7. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
8. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
9. Bullying Prevention Institute Designed to Empower Change in Schools
10. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
11. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the ... CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. ... across the United States. , “There are currently no approved drugs that address ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... , February 23, 2017 Tillotts ... the Berlin office was opened ... Kritikos . The portfolio includes Entocort ® for ... the treatment of ulcerative colitis, and VistaPrep ® ... the Swiss specialty pharmaceutical company focused on the treatment ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: